http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 09 Feb 2026 14:30:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Instil+Bio%2C+Inc.+++++++++++++++++++++++Filed+by%3A+BML+Investment+Partners%2C+L.P./25967438.html si-local-file:///var/storage/secattach/20260209/25967438.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Instil+Bio%2C+Inc.+++++++++++++++++++++++Filed+by%3A+BML+Investment+Partners%2C+L.P./25967438.html Mon, 09 Feb 2026 14:30:00 -0500 O.50204325 TIL http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Instil+Bio%2C+Inc.+++++++++++++++++++++++Filed+by%3A+BML+Investment+Partners%2C+L.P./25967438.html si-local-file:///var/storage/secattach/20260209/25967438.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Instil+Bio%2C+Inc.+++++++++++++++++++++++Filed+by%3A+BML+Investment+Partners%2C+L.P./25967438.html Mon, 09 Feb 2026 14:30:00 -0500 O.50204325 TIL http://www.streetinsider.com/Downgrades/H.C.+Wainwright+Downgrades+Instil+Bio+Inc+%28TIL%29+to+Neutral/25817909.html <p>H.C. Wainwright analyst Mitchell Kapoor downgraded Instil Bio Inc (NASDAQ: TIL) from Buy to Neutral.</p><p>For an analyst ratings summary and ratings history on Instil Bio Inc <a href="http://www.streetinsider.com/rating_history.php?q=TIL">click here</a>. For more ratings news on Instil Bio Inc <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TIL&amp;type=analyst">click here</a>.</p><p>Shares of Instil Bio Inc closed at $6.66 yesterday.</p> http://www.streetinsider.com/Downgrades/H.C.+Wainwright+Downgrades+Instil+Bio+Inc+%28TIL%29+to+Neutral/25817909.html Wed, 07 Jan 2026 09:01:20 -0500 TIL http://www.streetinsider.com/Analyst+Comments/Instil+Bio+%28TIL%29+Reiterated+at+Market+Perform+by+Citizens/25816261.html <p>Citizens analyst Reni Benjamin reiterated a Market Perform rating on Instil Bio Inc (NASDAQ: TIL).</p><p>The analyst commented, "We maintain our Market Perform rating for Instil Bio, and value the company based on a cash/share value analysis. Yesterday, Instil Bio announced that its subsidiary, Axion Bio, discontinued clinical development of AXN-2510 ('2510) and terminated the collaboration with ImmuneOnco. This action effectively ends all of Instil's disclosed programs, including that of its lead asset '2510, which was undergoing a Phase 1B/2 bridging study in r/r NSCLC. The company reported $83.4MM in cash for 3Q25, and we estimate a current cash position of http://www.streetinsider.com/Analyst+Comments/Instil+Bio+%28TIL%29+Reiterated+at+Market+Perform+by+Citizens/25816261.html Wed, 07 Jan 2026 05:11:23 -0500 TIL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Instil+Bio%2C+Inc.++++++++++For%3A+Jan+05/25814477.html si-local-file:///var/storage/secattach/20260106/25814477.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Instil+Bio%2C+Inc.++++++++++For%3A+Jan+05/25814477.html Tue, 06 Jan 2026 17:00:00 -0500 O.50204325 TIL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Instil+Bio%2C+Inc.++++++++++For%3A+Jan+05/25814477.html si-local-file:///var/storage/secattach/20260106/25814477.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Instil+Bio%2C+Inc.++++++++++For%3A+Jan+05/25814477.html Tue, 06 Jan 2026 17:00:00 -0500 O.50204325 TIL http://www.streetinsider.com/Downgrades/Baird+Downgrades+Instil+Bio+Inc+%28TIL%29+to+Neutral/25811807.html <p>Baird analyst Jack Allen downgraded Instil Bio Inc (NASDAQ: TIL) from Outperform to Neutral with a price target of $7.00 (from $180.00).</p><p>The analyst comments "Downgrading to Neutral given discontinuation of AXN-2510. This morning, Instil management announced they have terminated the licenses with ImmuneOnco (HKEX:1541, not covered) surrounding AXN-2510 and AXN-27M. We're disappointed by this news given the early encouraging data from AXN-2510 and our enthusiasm for the PD-(L)1xVEGF class. At this time, further details surrounding the decision to discontinue to AXN-2510 are not being disclosed, however, we suspect this decision was educated by evolving clinical data. Based on this update, http://www.streetinsider.com/Downgrades/Baird+Downgrades+Instil+Bio+Inc+%28TIL%29+to+Neutral/25811807.html Tue, 06 Jan 2026 12:12:19 -0500 TIL http://www.streetinsider.com/Analyst+PT+Change/Baird+Downgrades+Instil+Bio+Inc+%28TIL%29+to+Neutral/25811807.html <p>Baird analyst Jack Allen downgraded Instil Bio Inc (NASDAQ: TIL) from Outperform to Neutral with a price target of $7.00 (from $180.00).</p><p>The analyst comments "Downgrading to Neutral given discontinuation of AXN-2510. This morning, Instil management announced they have terminated the licenses with ImmuneOnco (HKEX:1541, not covered) surrounding AXN-2510 and AXN-27M. We're disappointed by this news given the early encouraging data from AXN-2510 and our enthusiasm for the PD-(L)1xVEGF class. At this time, further details surrounding the decision to discontinue to AXN-2510 are not being disclosed, however, we suspect this decision was educated by evolving clinical data. Based on this update, http://www.streetinsider.com/Analyst+PT+Change/Baird+Downgrades+Instil+Bio+Inc+%28TIL%29+to+Neutral/25811807.html Tue, 06 Jan 2026 12:12:19 -0500 TIL http://www.streetinsider.com/Analyst+Comments/Baird+Downgrades+Instil+Bio+Inc+%28TIL%29+to+Neutral/25811807.html <p>Baird analyst Jack Allen downgraded Instil Bio Inc (NASDAQ: TIL) from Outperform to Neutral with a price target of $7.00 (from $180.00).</p><p>The analyst comments "Downgrading to Neutral given discontinuation of AXN-2510. This morning, Instil management announced they have terminated the licenses with ImmuneOnco (HKEX:1541, not covered) surrounding AXN-2510 and AXN-27M. We're disappointed by this news given the early encouraging data from AXN-2510 and our enthusiasm for the PD-(L)1xVEGF class. At this time, further details surrounding the decision to discontinue to AXN-2510 are not being disclosed, however, we suspect this decision was educated by evolving clinical data. Based on this update, http://www.streetinsider.com/Analyst+Comments/Baird+Downgrades+Instil+Bio+Inc+%28TIL%29+to+Neutral/25811807.html Tue, 06 Jan 2026 12:12:19 -0500 TIL http://www.streetinsider.com/Trading+Halts/Instil+Bio+subsidiary+discontinues+AXN-2510+development%2C+ends+license+deal/25809241.html <p>Instil Bio Inc. (NASDAQ: TIL) announced that its subsidiary Axion Bio Inc. has discontinued clinical development of AXN-2510 and terminated its license and collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK).</p><p>Under the termination agreement, all rights previously licensed to Axion have reverted to ImmuneOnco. These rights included global development and commercial rights outside Greater China for both AXN-2510 and AXN-27M. Axion retains a limited license to complete the wind-down of its clinical development activities.</p><p>The announcement was made in a press release statement from the Dallas-based biopharmaceutical company. Instil Bio focuses on developing novel therapies through its various subsidiaries and http://www.streetinsider.com/Trading+Halts/Instil+Bio+subsidiary+discontinues+AXN-2510+development%2C+ends+license+deal/25809241.html Tue, 06 Jan 2026 07:01:15 -0500 TIL http://www.streetinsider.com/Corporate+News/Instil+Bio+subsidiary+discontinues+AXN-2510+development%2C+ends+license+deal/25809241.html <p>Instil Bio Inc. (NASDAQ: TIL) announced that its subsidiary Axion Bio Inc. has discontinued clinical development of AXN-2510 and terminated its license and collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK).</p><p>Under the termination agreement, all rights previously licensed to Axion have reverted to ImmuneOnco. These rights included global development and commercial rights outside Greater China for both AXN-2510 and AXN-27M. Axion retains a limited license to complete the wind-down of its clinical development activities.</p><p>The announcement was made in a press release statement from the Dallas-based biopharmaceutical company. Instil Bio focuses on developing novel therapies through its various subsidiaries and http://www.streetinsider.com/Corporate+News/Instil+Bio+subsidiary+discontinues+AXN-2510+development%2C+ends+license+deal/25809241.html Tue, 06 Jan 2026 07:01:15 -0500 TIL http://www.streetinsider.com/FDA/Instil+Bio+subsidiary+discontinues+AXN-2510+development%2C+ends+license+deal/25809241.html <p>Instil Bio Inc. (NASDAQ: TIL) announced that its subsidiary Axion Bio Inc. has discontinued clinical development of AXN-2510 and terminated its license and collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK).</p><p>Under the termination agreement, all rights previously licensed to Axion have reverted to ImmuneOnco. These rights included global development and commercial rights outside Greater China for both AXN-2510 and AXN-27M. Axion retains a limited license to complete the wind-down of its clinical development activities.</p><p>The announcement was made in a press release statement from the Dallas-based biopharmaceutical company. Instil Bio focuses on developing novel therapies through its various subsidiaries and http://www.streetinsider.com/FDA/Instil+Bio+subsidiary+discontinues+AXN-2510+development%2C+ends+license+deal/25809241.html Tue, 06 Jan 2026 07:01:15 -0500 TIL http://www.streetinsider.com/Hot+Corp.+News/Instil+Bio+subsidiary+discontinues+AXN-2510+development%2C+ends+license+deal/25809241.html <p>Instil Bio Inc. (NASDAQ: TIL) announced that its subsidiary Axion Bio Inc. has discontinued clinical development of AXN-2510 and terminated its license and collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK).</p><p>Under the termination agreement, all rights previously licensed to Axion have reverted to ImmuneOnco. These rights included global development and commercial rights outside Greater China for both AXN-2510 and AXN-27M. Axion retains a limited license to complete the wind-down of its clinical development activities.</p><p>The announcement was made in a press release statement from the Dallas-based biopharmaceutical company. Instil Bio focuses on developing novel therapies through its various subsidiaries and http://www.streetinsider.com/Hot+Corp.+News/Instil+Bio+subsidiary+discontinues+AXN-2510+development%2C+ends+license+deal/25809241.html Tue, 06 Jan 2026 07:01:15 -0500 TIL http://www.streetinsider.com/Hot+FDA+News/Instil+Bio+subsidiary+discontinues+AXN-2510+development%2C+ends+license+deal/25809241.html <p>Instil Bio Inc. (NASDAQ: TIL) announced that its subsidiary Axion Bio Inc. has discontinued clinical development of AXN-2510 and terminated its license and collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK).</p><p>Under the termination agreement, all rights previously licensed to Axion have reverted to ImmuneOnco. These rights included global development and commercial rights outside Greater China for both AXN-2510 and AXN-27M. Axion retains a limited license to complete the wind-down of its clinical development activities.</p><p>The announcement was made in a press release statement from the Dallas-based biopharmaceutical company. Instil Bio focuses on developing novel therapies through its various subsidiaries and http://www.streetinsider.com/Hot+FDA+News/Instil+Bio+subsidiary+discontinues+AXN-2510+development%2C+ends+license+deal/25809241.html Tue, 06 Jan 2026 07:01:15 -0500 TIL http://www.streetinsider.com/Press+Releases/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html <p align="left">DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) (“ImmuneOnco”) have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M (“Termination Agreement”).</p> <p>Under the terms of the Termination Agreement, all rights previously licensed to Axion, including global development and commercial rights outside Greater China, have reverted to ImmuneOnco, subject to a limited license to Axion to wind http://www.streetinsider.com/Press+Releases/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html Tue, 06 Jan 2026 07:00:00 -0500 A.50216362 O.50204325 O.52736955 TIL http://www.streetinsider.com/Press+Releases/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html <p align="left">DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) (“ImmuneOnco”) have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M (“Termination Agreement”).</p> <p>Under the terms of the Termination Agreement, all rights previously licensed to Axion, including global development and commercial rights outside Greater China, have reverted to ImmuneOnco, subject to a limited license to Axion to wind http://www.streetinsider.com/Press+Releases/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html Tue, 06 Jan 2026 07:00:00 -0500 A.50216362 O.50204325 O.52736955 TIL http://www.streetinsider.com/Press+Releases/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html <p align="left">DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) (“ImmuneOnco”) have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M (“Termination Agreement”).</p> <p>Under the terms of the Termination Agreement, all rights previously licensed to Axion, including global development and commercial rights outside Greater China, have reverted to ImmuneOnco, subject to a limited license to Axion to wind http://www.streetinsider.com/Press+Releases/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html Tue, 06 Jan 2026 07:00:00 -0500 A.50216362 O.50204325 O.52736955 TIL http://www.streetinsider.com/Press+Releases/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html <p align="left">DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) (“ImmuneOnco”) have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M (“Termination Agreement”).</p> <p>Under the terms of the Termination Agreement, all rights previously licensed to Axion, including global development and commercial rights outside Greater China, have reverted to ImmuneOnco, subject to a limited license to Axion to wind http://www.streetinsider.com/Press+Releases/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html Tue, 06 Jan 2026 07:00:00 -0500 A.50216362 O.50204325 O.52736955 TIL http://www.streetinsider.com/Globe+Newswire/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html <p align="left">DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) (“ImmuneOnco”) have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M (“Termination Agreement”).</p> <p>Under the terms of the Termination Agreement, all rights previously licensed to Axion, including global development and commercial rights outside Greater China, have reverted to ImmuneOnco, subject to a limited license to Axion to wind http://www.streetinsider.com/Globe+Newswire/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html Tue, 06 Jan 2026 07:00:00 -0500 A.50216362 O.50204325 O.52736955 TIL http://www.streetinsider.com/Globe+Newswire/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html <p align="left">DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) (“ImmuneOnco”) have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M (“Termination Agreement”).</p> <p>Under the terms of the Termination Agreement, all rights previously licensed to Axion, including global development and commercial rights outside Greater China, have reverted to ImmuneOnco, subject to a limited license to Axion to wind http://www.streetinsider.com/Globe+Newswire/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html Tue, 06 Jan 2026 07:00:00 -0500 A.50216362 O.50204325 O.52736955 TIL http://www.streetinsider.com/Globe+Newswire/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html <p align="left">DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) (“ImmuneOnco”) have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M (“Termination Agreement”).</p> <p>Under the terms of the Termination Agreement, all rights previously licensed to Axion, including global development and commercial rights outside Greater China, have reverted to ImmuneOnco, subject to a limited license to Axion to wind http://www.streetinsider.com/Globe+Newswire/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html Tue, 06 Jan 2026 07:00:00 -0500 A.50216362 O.50204325 O.52736955 TIL http://www.streetinsider.com/Globe+Newswire/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html <p align="left">DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) (“ImmuneOnco”) have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M (“Termination Agreement”).</p> <p>Under the terms of the Termination Agreement, all rights previously licensed to Axion, including global development and commercial rights outside Greater China, have reverted to ImmuneOnco, subject to a limited license to Axion to wind http://www.streetinsider.com/Globe+Newswire/Instil+Bio%E2%80%99s+Subsidiary+Discontinues+Clinical+Development+of+AXN-2510+and+Terminates+License+and+Collaboration+Agreement+with+ImmuneOnco/25809163.html Tue, 06 Jan 2026 07:00:00 -0500 A.50216362 O.50204325 O.52736955 TIL http://www.streetinsider.com/Trading+Halts/Instil+Bio+Inc.+%28TIL%29+Halted%2C+News+Pending/25809099.html <p>Instil Bio Inc. (NASDAQ: TIL) Halted, News Pending<br /> </p> http://www.streetinsider.com/Trading+Halts/Instil+Bio+Inc.+%28TIL%29+Halted%2C+News+Pending/25809099.html Tue, 06 Jan 2026 06:58:42 -0500 TIL http://www.streetinsider.com/Analyst+Comments/Instil+Bio+%28TIL%29+Shares+are+Fairly+Valued+Till+Phase+2+Dose+Results+-+Citizens/25627208.html <p>Citizens analyst Reni Benjamin reiterated a Market Perform rating on Instil Bio Inc (NASDAQ: TIL).</p><p>The analyst commented, "We maintain our Market Perform rating on Instil Bio based on a cash/share and platform value analysis. Recently, Instil reported 3Q25 financial results and clinical trial progress, including an announcement that, in October, the company had dosed the first patient in its U.S.-based Phase 1B/2 doseescalation bridging study. The company also highlighted partner ImmuneOnco’s (NC) presentation of ‘2510 monotherapy in relapsed/refractory NSCLC. While the company’s trials are progressing on schedule, and promising updated NSCLC data were presented, we remain on the sidelines and http://www.streetinsider.com/Analyst+Comments/Instil+Bio+%28TIL%29+Shares+are+Fairly+Valued+Till+Phase+2+Dose+Results+-+Citizens/25627208.html Tue, 18 Nov 2025 04:48:10 -0500 TIL http://www.streetinsider.com/Earnings/Instil+Bio+Inc.+%28TIL%29+Misses+Q3+EPS+by+175c/25608430.html <p>Instil Bio Inc. (NASDAQ: TIL) reported Q3 EPS of ($1.75).</p><p>For earnings history and earnings-related data on Instil Bio Inc. (TIL) <a href="http://www.streetinsider.com/ec_earnings.php?q=TIL">click here</a>.</p> http://www.streetinsider.com/Earnings/Instil+Bio+Inc.+%28TIL%29+Misses+Q3+EPS+by+175c/25608430.html Thu, 13 Nov 2025 16:57:10 -0500 TIL